BPTH:NSD-Bio-Path Holdings, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.50

Change

+0.02 (+0.57)%

Market Cap

USD 0.02B

Volume

0.08M

Average Target Price

USD 11.00 (+214.29%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome; and in Phase IIa clinical trials for the treatment of chronic myeloid leukemia, as well as to treat solid tumors. The company is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+8.61 (+3.95%)

USD56.71B 21.08 16.42
REGN Regeneron Pharmaceuticals, Inc

+5.74 (+1.13%)

USD54.24B 20.76 16.02
MRNA Moderna, Inc

+17.85 (+16.35%)

USD43.20B N/A N/A
SGEN Seagen Inc

+3.67 (+2.22%)

USD29.62B 62.48 65.81
ALXN Alexion Pharmaceuticals, Inc

+0.90 (+0.73%)

USD26.90B 28.53 26.40
RPRX Royalty Pharma plc

+0.63 (+1.54%)

USD25.62B 22.60 9.61
BNTX BioNTech SE

+5.03 (+4.79%)

USD25.27B -99,999.99 N/A
GMAB Genmab A/S

+1.22 (+3.40%)

USD23.59B 26.59 2.65
BGNE BeiGene, Ltd

+21.73 (+8.23%)

USD23.12B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing BPTH

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -56.20% 11% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -56.20% 11% F 5% F
Trailing 12 Months  
Capital Gain -51.72% 13% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.72% 13% F 5% F
Trailing 5 Years  
Capital Gain -98.89% 6% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -98.89% 6% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain -47.22% N/A N/A 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.22% N/A N/A 1% F
Risk Return Profile  
Volatility (Standard Deviation) 59.66% N/A N/A 18% F
Risk Adjusted Return -79.15% N/A N/A 7% F
Market Capitalization 0.02B 5% F 6% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.20 94% A 72% C-
Price / Cash Flow Ratio -1.88 23% F 64% D
EV/EBITDA 0.22 64% D 94% A
Management Effectiveness  
Return on Equity -73.41% 45% F 16% F
Return on Invested Capital -77.95% 36% F 12% F
Return on Assets -41.46% 24% F 7% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.10 97% A+ 96% A
Short Percent 5.02% 59% F 39% F
Beta 2.25 17% F 9% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.